Grey Street Capital’s AstraZeneca AZN Stock Holding History

Grey Street Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$925K	Buy	+6,830	New	+$904K	0.13%	187

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Grey Street Capital's AZN Position: Q1 2024 in Review

Grey Street Capital opened a new position in AstraZeneca (AZN) in Q1 2024: 6,830 shares worth $925K. The stake represents 0.13% of the portfolio and ranks #187 among its holdings.

1,142 funds tracked by Wall St. Rank hold AZN as of Q1 2024.

Grey Street Capital held 6,830 shares of AstraZeneca worth $925K as of Q1 2024.
AstraZeneca was a new Grey Street Capital position in Q1 2024.
AstraZeneca made up 0.13% of Grey Street Capital's portfolio in Q1 2024, its #187 holding.
1,142 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.

Based on Grey Street Capital's 13F filing for Q1 2024, filed 9 Aug 2024.